John Pineda

Statistics

Publications

Citations

990

H-Index

Active since

2018

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Zhongshan Hospital

Fudan University

Johns Hopkins Medicine

Cornell University

John Pineda is an author at Memorial Sloan Kettering Cancer Center specializing in chimeric antigen receptor t-cell therapy, cancer immunotherapy, and immunotherapy.

ORCID

Publications per year

2018–2022

Publications

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Prasad S. Adusumilli, Marjorie G. Zauderer, Isabelle Rivière et al. · Cancer Discovery · 2021 · 560 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial

Sham Mailankody, Arnab Ghosh, Terence J. Purdon et al. · Blood · 2018 · 100 citations

Medicine, Oncology, Pharmacokinetics +17

Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent.

Prasad S. Adusumilli, Marjorie G. Zauderer, Valerie W. Rusch et al. · Journal of Clinical Oncology · 2019 · 92 citations

Pharmacy, Immunology, Oncology +17

Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy

Prasad S. Adusumilli, Marjorie G. Zauderer, Valerie W. Rusch et al. · Cancer Research · 2019 · 53 citations

Life Sciences, Immunology, Oncology +17

A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL "Armored" CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Transformation

Jae H. Park, Maria Lia Palomba, Connie Lee Batlevi et al. · Blood · 2018 · 45 citations

Life Sciences, Hematology, Immunology +17

1–5 of 11